Dr. Sylvia Mohen is a board-certified Neurologist and Pain Management specialist with more than a decade of clinical experience. She provides comprehensive care across the full spectrum of neurological conditions, including migraine and other headache disorders, epilepsy, dementia, stroke and other cerebrovascular diseases, peripheral neuropathy, Parkinson’s disease and other movement disorders.
She completed her internship, Neurology residency, and Epilepsy fellowship at Albert Einstein College of Medicine/Montefiore Medical Center, where she developed advanced expertise in seizure disorders, headache medicine, and comprehensive neurologic care.
Dr. Mohen has extensive experience caring for women across all life stages. She regularly supports patients through pregnancy with conditions such as migraine and epilepsy and understands the unique neurologic challenges related to menopause. She also works closely with patients who have overlapping rheumatologic and neurologic disorders, helping them navigate complex symptoms that affect function and well-being.
With more than 10 years of clinical experience using neurotoxin therapy, she offers Botox, Xeomin, Daxxify, and Dysport for migraine, cervical dystonia, chronic pain syndromes, and hyperhidrosis, tailoring each treatment to the individual.
Dr. Mohen is also a researcher with NYNA’s New York Neurology Institute, where she supervises multiple ongoing clinical trials. She has direct experience with newer treatments for dementia and frequently provides patients access to emerging therapies through active research studies.
She chose neurology because she was drawn to the observation-based skills that define the specialty, along with a longstanding appreciation for influential neurologic writers. As a practitioner, she values the opportunity to build long-term relationships and finds it deeply rewarding to help patients navigate neurologic disorders through life’s milestones.
Her approach is individualized and holistic, with a strong emphasis on communication, collaboration, and evidence-based strategies designed to support long-term neurological health and overall quality of life.
Dr. Sylvia Mohen is a board-certified Neurologist and Pain Management specialist with more than a decade of clinical experience. She provides comprehensive care across the full spectrum of neurological conditions, including migraine and other headache disorders, epilepsy, dementia, stroke and other cerebrovascular diseases, peripheral neuropathy, Parkinson’s disease and other movement disorders.
Wake Forest University School of Medicine, Winston-Salem NC
Doctor of Medicine, May 2009
Albert Einstein College of Medicine of Yeshiva University
Montefiore Medical Center, Bronx NY
Clinical Neurophysiology Fellow, EEG and Epilepsy Track, Department of Neurology
2013-2014
2024 – Ongoing, Sub- Investigator
A Phase IV, Open-label Study of Cenobamate Monotherapy in Adult Subjects with Newly Diagnosed or Recurrent Partial-Onset
Sponsor: YKP3089C049
2022 – Ongoing, Sub- Investigator
Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of Rimegepant for the treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < 18 years of age
Sponsor: Biohaven Pharmaceuticals, Inc.
2022 – Ongoing, Sub- Investigator
Phase 3, multicenter, open-label study to assess the long-term safety and tolerability of rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < 18 years of age
Sponsor: Biohaven Pharmaceuticals, Inc.
2022 – Ongoing, Sub- Investigator
A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
Sponsor: Biohaven Pharmaceuticals, Inc.
2022 – 2024 Sub- Investigator
Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention
Sponsor: AEON Biopharma Inc.
2021 – 2023, Sub- Investigator
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
Sponsor: Biohaven Pharmaceuticals, Inc.
2019 – 2020, Sub- Investigator
A Randomized, Multicenter, Double-Blind, Parallel, Sham-Controlled Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for the Prevention of Migraines.
Sponsor: electroCore, Inc
2019 – 2020, Sub- Investigator
Nerve conduction velocity sub-study associated with a Phase III, randomized, double-blind, placebo- controlled trial. Efficacy and safety study of Balovaptan in adults with autism spectrum disorder with a 2 year open-label extension.
Sponsor: F. Homann-La Roche Ltd
2023- 2024, Sub-Investigator
An Open-Label, Long- Term Extension Study to Evaluate The Safety and Tolerability of Simufilam 100 MG Tablets In Participants With Mild To Moderate Alzheimer’s Disease
Sponsor: Cassava Sciences, Inc.
2022 – 2024, Sub- Investigator
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Study Evaluating The Safety And Efficacy Of Simufilam 100 Mg Tablets In Subjects With Mild-To-Moderate Alzheimer’s Disease
Sponsor: Cassava Sciences, Inc.
2021- 2023, Sub-Investigator
A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Study of NE3107 in Subjects Who Have Mild to Moderate Alzheimer’s Disease
Sponsor: NeurMedix, Inc.
2020 – 2021, Sub- Investigator
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients with Mild to Moderate Alzheimer’s Disease.
Sponsor: AriBio Co., Ltd
2020 – 2021, Sub- Investigator
A Multicenter, Placebo-Controlled, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette’s Syndrome.
Sponsor: Emalex Biosciences, Inc.
2022- 2023, Sub- Investigator
A Phase 2a, Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Effects of CST-2032 and CST-107 on Cognition in Subjects with Mild Cognitive Impairment or Mild Dementia due to Parkinson’s or Alzheimer’s Disease
Sponsor: Curasen Therapeutics, Inc.
2021 – 2021, Sub- Investigator
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson’s Disease Patients with Motor Fluctuations
Sponsor: Cerevance Beta, Inc.
2015 – 2016, Sub- Investigator
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson’s Disease.
Sponsor: Sunovion Pharmaceuticals
2022 – 2022 Sub- Investigator
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy Of AbobotulinumtoxinA (Dysport®)in Comparison with Onabotulinumtoxin (Botox®) when Treating Adults with Upper Limb Spasticity
Sponsor: Ipsen Pharma
2024 -Ongoing Sub- Investigator
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
Sponsor: IQVIA
Profile Details
Board Certifications
American Board of Psychiatry and Neurology: Board Certified 2013
American Board of Pain Medicine: Board Certified 2022
Specialties:
Headache Medicine (including chronic migraine, cluster, trigeminal neuralgia, hemicranial continua, occipital neuralgia, menstrual migraine)
Botox therapy for chronic migraines, cervical dystonia, orofacial dystonia, hemifacial spasm, spasticity, neuropathic pain, hyperhidrosis, sialorrhea
Facial Pain
Epilepsy
Dementia
Tinnitus
Vertigo and Dizziness
Hyperhidrosis
Clinical Neurophysiology
Menstrual associated migraine
Migraine in Pregnancy
Neck pain and spasm
TMJ
Sleep disorders including narcolepsy, REM disordered behavior,
Hypersomnia
Confusion and brain fog
